维康药业
(300878)
| 流通市值：44.10亿 | | | 总市值：44.31亿 |
| 流通股本：1.44亿 | | | 总股本：1.45亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 69,661,950.22 | 225,272,638.73 | 151,317,754.3 | 114,569,884.83 |
| 营业收入 | 69,661,950.22 | 225,272,638.73 | 151,317,754.3 | 114,569,884.83 |
| 二、营业总成本 | 59,200,096.66 | 324,809,022.52 | 250,194,085.06 | 173,950,785.44 |
| 营业成本 | 28,213,495.11 | 155,292,116.51 | 128,101,243.85 | 89,624,143.06 |
| 税金及附加 | 2,176,660.68 | 7,597,232.65 | 4,446,881.58 | 1,868,155.04 |
| 销售费用 | 16,691,871.31 | 106,894,703.46 | 74,629,801.07 | 53,286,353.94 |
| 管理费用 | 9,541,350.85 | 40,713,417.63 | 30,723,857.75 | 20,193,443.14 |
| 研发费用 | 2,070,853.96 | 9,371,333.13 | 7,664,570.9 | 5,995,845.17 |
| 财务费用 | 505,864.75 | 4,940,219.14 | 4,627,729.91 | 2,982,845.09 |
| 其中:利息费用 | 5,659,028.07 | 6,273,431.92 | 5,659,028.07 | 3,782,750.26 |
| 其中:利息收入 | 1,108,946.45 | 1,356,985.87 | 1,108,946.45 | 848,072.42 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | -12,478,791.23 | - | - |
| 加:投资收益 | 263,572.05 | - | - | - |
| 资产处置收益 | - | -992,596.01 | -1,002,485.43 | -493,861.61 |
| 资产减值损失(新) | -502,303.13 | -95,621,581.13 | -20,845,233.95 | -5,002,495.31 |
| 信用减值损失(新) | -2,738,495.73 | -1,914,089.44 | 8,828,033.75 | 6,894,944.48 |
| 其他收益 | 1,954,781.05 | 9,000,017.97 | 6,947,927.38 | 3,492,485.37 |
| 四、营业利润 | 9,439,407.8 | -201,543,423.63 | -104,948,089.01 | -54,489,827.68 |
| 加:营业外收入 | 16,123.75 | 965,333.41 | 754,553.47 | 255,442.25 |
| 减:营业外支出 | 3,735,042.68 | 7,897,021.58 | 7,823,272.09 | 2,047,875.44 |
| 五、利润总额 | 5,720,488.87 | -208,475,111.8 | -112,016,807.63 | -56,282,260.87 |
| 减:所得税费用 | 3,877,323.87 | 21,256,694.67 | 11,808,721.1 | 8,028,798.56 |
| 六、净利润 | 1,843,165 | -229,731,806.47 | -123,825,528.73 | -64,311,059.43 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,843,165 | -229,731,806.47 | -123,825,528.73 | -64,311,059.43 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,743,206.76 | -227,341,721.82 | -123,854,579.87 | -64,219,669.11 |
| 少数股东损益 | 99,958.24 | -2,390,084.65 | 29,051.14 | -91,390.32 |
| 扣除非经常损益后的净利润 | 3,325,462.37 | -214,567,929.48 | -122,188,938.22 | -64,826,322.34 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | -1.57 | -0.86 | -0.44 |
| (二)稀释每股收益 | 0.01 | -1.57 | -0.86 | -0.44 |
| 九、综合收益总额 | 1,843,165 | -229,731,806.47 | -123,825,528.73 | -64,311,059.43 |
| 归属于母公司股东的综合收益总额 | 1,743,206.76 | -227,341,721.82 | -123,854,579.87 | -64,219,669.11 |
| 归属于少数股东的综合收益总额 | 99,958.24 | -2,390,084.65 | 29,051.14 | -91,390.32 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-30 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |